Trypanosoma cruzi strains resistant to benznidazole occurring in Colombia;Sensibilidad al benzonidazol de cepas de trypanosoma cruzi sugiere la circulación de cepas naturalmente resistentes en Colombia

Biomedica

Volumn 32, Issue 2, 2012, Pages 196-205

  Mejía Jaramillo, Ana María ^a   Fernández, Geysson Javier ^a   Montilla, Marleny ^b   Nicholls, Rubén Santiago ^b   Triana Chávez, Omar ^a  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^b INSTITUTO NACIONAL DE SALUD   (Colombia)

Author keywords

Chagas disease therapy; immunity; innate; Colombia; Trypanosoma cruzi

Indexed keywords

ANTITRYPANOSOMAL AGENT; BENZNIDAZOLE; NITROIMIDAZOLE DERIVATIVE;

ANIMAL; ANIMAL DISEASE; ARTICLE; CHAGAS DISEASE; COLOMBIA; DISEASE CARRIER; DRUG EFFECT; DRUG RESISTANCE; ECOLOGY; HUMAN; ISOLATION AND PURIFICATION; OPOSSUM; PANSTRONGYLUS; PARASITOLOGY; RAT; RHODNIUS; RODENT DISEASE; SPECIES DIFFERENCE; TRIATOMA; TRYPANOSOMA CRUZI;

ANIMALS; CHAGAS DISEASE; COLOMBIA; DRUG RESISTANCE; ECOLOGY; HUMANS; INSECT VECTORS; NITROIMIDAZOLES; OPOSSUMS; PANSTRONGYLUS; RATS; RHODNIUS; RODENT DISEASES; SPECIES SPECIFICITY; TRIATOMA; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

MAMMALIA; TRYPANOSOMA CRUZI;

EID: 84869839186     PISSN: 01204157     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Pinto-Dias J, Schofield C. Social and medical aspects: Morbidity and mortality in general population. En: Telleria J, Tibayrenc M, editors. American trypanosomiasis Chagas disease. One hundred years of research. First edition. London: Elsevier; 2010. p. 45-54.
2. Patterson J, Guhl F. Geographical distribution of Chagas disease. En: Telleria J, Tibayrenc M, editors. American trypanosomiasis Chagas disease. One hundred years of research. First edition. London: Elsevier; 2010. p. 83-114.
3. Moncayo A, Silveira A. Current trends and future prospects for control of Chagas disease. En: Telleria J, Tibayrenc M, editors. American trypanosomiasis Chagas disease. One hundred years of research. First edition. London: Elsevier; 2010. p. 55-82.
4. Moncayo A. Chagas disease: Current epidemiological trends after the interruption of vectorial and transfusional transmission in the Southern Cone countries. Mem Inst Oswaldo Cruz. 2003;98:577-91.
5. López-Antuñano FJ. Quimioterapia de las infecciones producidas por Trypanosoma cruzi. Salud Pública Mex. 1997;39:463-71.
6. Rodrigues J, Castro S. A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz. 2002;97:3-24.
7. Wilkinson SR, Kelly JM. Trypanocidal drugs: Mechanisms, resistance and new targets. Expert Rev Mol Med. 2009;11:1-24.
8. Filardi LS, Brener Z. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Trans R Soc Trop Med Hyg. 1987;81:755-9.
9. Hayes JD, Wolf CR. Molecular mechanisms of drug resistance. Biochem J. 1990;272:281-95.
10. Ouellette M. Biochemical and molecular mechanisms of drug resistance in parasites. Trop Med Int Health. 2001;6:874-82.
11. Singh N. Drug resistance mechanisms in clinical isolates of Leishmania donovani. Indian J Med Res. 2006;123:411-22.
12. Mejía-Jaramillo AM, Fernández GJ, Palacio L, Triana O. Gene expression study using real-time PCR identifies an NTR gene as a major marker of resistance to beznidazole in Trypanosoma cruzi. Parasit Vectors. 2011;4:1-12.
13. Wilkinson SR, Taylor MC, Horn D, Kelly JM, Cheeseman I. A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc Natl Acad Sci USA. 2008;105:5022-7.
14. Villarreal D, Nirde P, Hide M, Barnabe C, Tibayrenc M. Differential gene expression in benznidazole-resistant Trypanosoma cruzi parasites. Antimicrob Agents Chemother. 2005;49:2701-9.
15. Nirdé P, Larroque C, Barnabé C. Drug-resistant epimastigotes of Trypanosoma cruzi and persistence of this phenotype after differentiation into amastigotes. C R Acad Sci Ser. 1995;318:1239-44.
16. Andrade HM, Murta SM, Chapeaurouge A, Perales J, Nirdé P, Romanha AJ. Proteomic analysis of Trypanosoma cruzi resistance to benznidazole. J Proteome Res. 2008;7:2357-67.
17. Campos FM, Liarte DB, Mortara RA, Romanha AJ, Murta SM. Characterization of a gene encoding alcohol dehydroge- nase in benznidazole-susceptible and -resistant populations of Trypanosoma cruzi. Acta Trop. 2009;111:56-63.
18. Murta SM, Krieger MA, Montenegro LR, Campos FF, Probst CM, Avila AR, et al. Deletion of copies of the gene encoding old yellow enzyme (TcOYE), a NAD(P) H flavin oxidoreductase, associates with in vitro-induced benznidazole resistance in Trypanosoma cruzi. Mol Biochem Parasitol. 2006;146:151-62.
19. Murta SM, Nogueira FB, dos Santos PF, Campos FF, Volpe C, Liarte DB, et al. Differential gene expression in Trypanosoma cruzi populations susceptible and resistant to benznidazole. Acta Trop. 2008;107:59-65.
20. Nogueira FB, Krieger MA, Nirde P, Goldenberg S, Romanha AJ, Murta SM. Increased expression of iron- containing superoxide dismutase-A (TcFeSOD-A) enzyme in Trypanosoma cruzi population with in vitro-induced resistance to benznidazole. Acta Trop. 2006;100:119-32.
21. Nogueira FB, Ruiz JC, Robello C, Romanha AJ, Murta SM. Molecular characterization of cytosolic and mitochondrial tryparedoxin peroxidase in Trypanosoma cruzi populations susceptible and resistant to benznidazole. Parasitol Res. 2009;104:835-44.
22. Villarreal D, Barnabe C, Sereno D, Tibayrenc M. Lack of correlation between in vitro susceptibility to benznidazole and phylogenetic diversity of Trypanosoma cruzi, the agent of Chagas disease. Exp Parasitol. 2004;108:24-31.
23. Murta SM, Gazzinelli RT, Brener Z, Romanha AJ. Molecular characterization of susceptible and naturally resistant strains of Trypanosoma cruzi to benznidazole and nifurtimox. Mol Biochem Parasitol. 1998;93:203-14.
24. Guhl F, Nicholls R, Montoya R, Rosas F, Velasco V, Mora E, et al. Rapid negativization of serology after treatment with benznidazole for Chagas disease in a group of Colombian schoolchildren. Proceedings of the IX European Multicolloquim of Parasitology. Valencia: Medimond International Proceedings; 2004. p. 107-14.
25. Padilla J. Situación de la enfermedad de Chagas en Colombia. Primer Taller Internacional Sobre Control de la Enfermedad de Chagas, Curso de diagnóstico, manejo y tratamiento de la enfermedad de Chagas, VI Reunión de la Iniciativa Andina para el Control de la Enfermedad de Chagas. Bogotá: CIMPAT; 2005. p. 19-22.
26. Guhl F, Angulo V, Restrepo M, Nicholls S, Montoya R. Estado del arte de la enfermedad de Chagas en Colombia y estrategias de control. Biomédica. 2003;23:31-3.
27. Reed GF, Lynn F, Meade BD. Use of coefficient of variation in assessing variability of quantitative assays. Clin Diagn Lab Immunol. 2002;9:1235-9.
28. Guhl F, Lazdins-Helds J. Grupo de trabajo científico sobre la enfermedad de Chagas. Buenos Aires: Organización Mundial de la Salud; 2007.
29. Urbina JA, Docampo R. Specific chemotherapy of Chagas disease: Controversies and advances. Trends Parasitol. 2003;19:495-501.
30. Buckner FS, Navabi N. Advances in Chagas disease drug development: 2009-2010. Curr Opin Infect Dis. 2010; 23:609-16.
31. Boiani M, Boiani L, Merlino A, Hernández P, Chidichimo A, Cazzulo JJ, et al. Second generation of 2H-benzimidazole 1,3-dioxide derivatives as anti-trypanosomatid agents: Synthesis, biological evaluation, and mode of action studies. Eur J Med Chem. 2009;44:4426-33.
32. Boiani M, Piacenza L, Hernández P, Boiani L, Cerecetto H, González M, et al. Mode of action of nifurtimox and N-oxide-containing heterocycles against Trypanosoma cruzi: Is oxidative stress involved? Biochem Pharmacol. 2010;79:1736-45.
33. Castro D, Boiani L, Benítez D, Hernández P, Merlino A, Gil C, et al. Anti-trypanosomatid benzofuroxans and deoxygenated analogues: Synthesis using polymer- supported triphenylphosphine, biological evaluation and mechanism of action studies. Eur J Med Chem. 2009;44:5055-65.
34. Gerpe A, Álvarez G, Benítez D, Boiani L, Quiroga M, Hernández P, et al. 5-Nitrofuranes and 5-nitrothiophenes with anti-Trypanosoma cruzi activity and ability to accumulate squalene. Bioorg Med Chem. 2009;17:7500-9.
35. Gerpe A, Boiani L, Hernández P, Sortino M, Zacchino S, González M, et al. Naftifine-analogues as anti-Trypanosoma cruzi agents. Eur J Med Chem. 2010;45:2154-64.
36. Pagano M, Demoro B, Toloza J, Boiani L, González M, Cerecetto H, et al. Effect of ruthenium complexation on trypanocidal activity of 5-nitrofuryl containing thiosemicarbazones. Eur J Med Chem. 2009;44:4937-43.
37. Rodríguez J, Arán VJ, Boiani L, Olea-Azar C, Lavaggi ML, González M, et al. New potent 5-nitroindazole derivatives as inhibitors of Trypanosoma cruzi growth: Synthesis, biological evaluation, and mechanism of action studies. Bioorg Med Chem. 2009;17:8186-96.
38. Urbina JA. Specific chemotherapy of Chagas disease: Relevance, current limitations and new approaches. Acta Trop. 2010;115:55-68.
39. Maya JD, Cassels BK, Iturriaga-Vásquez P, Ferreira J, Faundez M, Galanti N, et al. Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host. Comp Biochem Physiol A Mol Integr Physiol. 2007;146:601-20.
40. Maya JD, Bollo S, Núñez-Vergara LJ, Squella JA, Repetto Y, Morello A, et al. Trypanosoma cruzi: Effect and mode of action of nitroimidazole and nitrofuran derivatives. Biochem Pharmacol. 2003;65:999-1006.
41. Hall BS, Wu X, Hu L, Wilkinson SR. Exploiting the drug- activating properties of a novel trypanosomal nitroreductase. Antimicrob Agents Chemother. 2010;54:1193-9.
42. Hall BS, Bot C, Wilkinson SR. Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites. J Biol Chem. 2011;286:13088-95.
43. Toledo MJ, Bahia MT, Carneiro CM, Martins-Filho OA, Tibayrenc M, Barnabe C, et al. Chemotherapy with benznidazole and itraconazole for mice infected with different Trypanosoma cruzi clonal genotypes. Antimicrob Agents Chemother. 2003;47:223-30.
44. Veloso VM, Carneiro CM, Toledo MJ, Lana M, Chiari E, Tafuri WL, et al. Variation in susceptibility to benznidazole in isolates derived from Trypanosoma cruzi parental strains. Mem Inst Oswaldo Cruz. 2001;96:1005-11.
45. Camandaroba EL, Reis EA, Goncalves MS, Reis MG, Andrade SG. Trypanosoma cruzi: Susceptibility to chemotherapy with benznidazole of clones isolated from the highly resistant Colombian strain. Rev Soc Bras Med Trop. 2003;36:201-9.
46. Triana O, Mejía A, Zapata C, Arboleda A, Dib J. Caracterización genética y sensibilidad al benzonidazole de cepas colombianas de Trypanosoma cruzi. Biomédica. 2005;25:82-5.
47. Luna KP, Hernández IP, Rueda CM, Zorro MM, Croft SL, Escobar P. In vitro susceptibility of Trypanosoma cruzi strains from Santander, Colombia, to hexadecylphosphocholine (miltefosine), nifurtimox and benznidazole. Biomédica. 2009;29:448-55.
48. Murta SM, Romanha AJ. In vivo selection of a population of Trypanosoma cruzi and clones resistant to benznidazole. Parasitol. 1998;116:165-71.
49. Moreno M, D'ávila DA, Silva MN, Galvão LM, Macedo AM, Chiari E, et al. Trypanosoma cruzi benznidazole susceptibility in vitro does not predict the therapeutic outcome of human Chagas disease. Mem Inst Oswaldo Cruz. 2010;105:918-24.
50. Tibayrenc M, Ward P, Moya A, Ayala FJ. Natural populations of Trypanosoma cruzi, the agent of Chagas disease, have a complex multiclonal structure. Proc Natl Acad Sci USA. 1986;83:115-9.
51. Macedo AM, Machado CR, Oliveira RP, Pena SD. Trypanosoma cruzi: genetic structure of populations and relevance of genetic variability to the pathogenesis of Chagas disease. Mem Inst Oswaldo Cruz. 2004;99:1-12.
52. Borst P, Oullette M. New mechanism of drug resistance in parasitic protozoa. Annu Rev Microbiol. 1995;49:427-60.
53. El Fadili K, Messier N, Leprohon P, Roy G, Guimond C, Trudel N, et al. Role of the ABC transporter MRPA (PGPA) in antimony resistance in Leishmania infantum axenic and intracellular amastigotes. Antimicrob Agents Chemother. 2005;49:1988-93.
54. Ouellette M, Legare D, Papadopoulou B. Multidrug resistance and ABC transporters in parasitic protozoa. J Mol Microbiol Biotechnol. 2001;3:201-6.
55. Singh AK, Papadopoulou B, Ouellette M. Gene amplification in amphotericin B-resistant Leishmania tarentolae. Exp Parasitol. 2001;99:141-7.